Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and low-dose cyclophosphamide in castration- and docetaxel-resistant prostate cancer
NL-OMON35076Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus and cyclophosphamide in prostate cancer (PCa) (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Change in phosphorylation of 4E-BP1 and p70S6K in prostate biopsies. Planned start Oct 2010; status: withdrawn.
02
Drugs
everolimuscyclophosphamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON35076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35076.